For the quarter ending 2025-09-30, SRPT had -$492,387K decrease in cash & cash equivalents over the period. -$435,066K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -430,563 | - |
| Loss on debt extinguishment | -138,613 | - |
| Stock-based compensation expense | 93,380 | - |
| In-kind milestone payment to arrowhead pharmaceuticals | 50,000 | - |
| Depreciation and amortization expense | 39,268 | - |
| Loss on investment in arrowhead pharmaceuticals | -17,293 | - |
| Non-cash write-off of prepaid deposits | 17,041 | - |
| Reduction in the carrying amounts of the right of use assets | 11,326 | - |
| Change in the fair value of derivatives | -11,100 | - |
| Accretion of investment discount, net | -4,911 | - |
| Termination charges | 0 | - |
| Other | -4,439 | - |
| Decrease (increase) in accounts receivable | -206,249 | - |
| Decrease (increase) in manufacturing-related deposits and prepaids | -67,072 | - |
| Increase in inventory | 319,568 | - |
| Increase in other assets | 100,070 | - |
| Increase (decrease) in deferred revenue | 30,193 | - |
| Decrease in accounts payable, accrued expenses, lease liabilities and other liabilities | -145,347 | - |
| Net cash used in operating activities | -336,685 | - |
| Purchase of property and equipment | 98,381 | - |
| Purchase of available-for-sale securities | 44,658 | - |
| Maturity and sales of available-for-sale securities | 195,935 | - |
| Purchase of intangible assets and other | 7,738 | - |
| Acquisition of strategic investments | -245,819 | - |
| Proceeds from sale of investment in arrowhead pharmaceuticals | 174,095 | - |
| Net cash used in investing activities | -26,566 | - |
| Proceeds from exercise of stock options and purchase of stock under the employee stock purchase program | 18,395 | - |
| Repayment of 2027 notes | 123,333 | - |
| Debt issuance costs for the exchange transaction (defined in note 14) | 12,787 | - |
| Proceeds from issuance of common stock | 20,000 | - |
| Common stock issuance costs | 2,276 | - |
| Repurchases of common stock | 25,013 | - |
| Restricted cash in other assets | - | 15,600 |
| Payments related to revolving credit facility | 4,122 | - |
| Cash and cash equivalents | - | 510,600 |
| Net cash (used in) provided by financing activities | -129,136 | - |
| Total cash, cash equivalents and restricted cash | - | 526,177 |
| Decrease in cash, cash equivalents and restricted cash | -492,387 | - |
Sarepta Therapeutics, Inc. (SRPT)
Sarepta Therapeutics, Inc. (SRPT)